Related Experiment Video
Updated: Jun 29, 2026

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
Published on: March 30, 2017
Particulate drug interactions with polymeric and elastomeric valve components in suspension formulations for metered
Jeff James1, Martyn Davies, Richard Toon
1Laboratory of Biophysics and Surface Analysis, School of Pharmacy, The University of Nottingham, Nottingham, UK. paxjj@nottingham.ac.uk
Purpose:
To characterise the adhesive interactions between three pulmonary active pharmaceutical ingredient (API) materials and the components of pressurised metered dose inhalers (pMDIs) obtained from two commercially available products (termed 'Prod-1' and 'Prod-2'). This is of potential interest, as a greater understanding of the interactions between specific APIs and surfaces may aid manufacturers in component selection during pMDI system development.
Methods:
The theoretical work of adhesion (DeltaG(132)) for each API-pMDI component interaction was calculated using the surface component analysis (SCA) approach. These results were correlated with corresponding API-pMDI component separation energy measurements determined using colloid probe AFM.
Results:
Strong correlations existed between separation energy and the DeltaG(132) parameters where the polar contribution was accounted for. This highlighted the adhesive influence of polar surface energy on each interaction in this study. Generally the largest adhesive interactions involved APIs and pMDI components which have a bipolar surface energy (i.e. both gamma(-) and gamma(+) >1 mJ m(-2)).
Conclusions:
For each API-pMDI interaction in this study, the polar component of surface energy has the greater influence on adhesive events. The bipolar surface energetics of certain APIs and pMDI components were deemed responsible for the increased adhesive interactions observed with these materials. This study highlights that different materials can have different effects on the adhesive interactions with particulate APIs; information that could aid the manufacturer in producing more effective and efficient pMDI systems.
Related Concept Videos
Inhaled Medications
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Modified-Release Drug Delivery Systems: Influencing Factors
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Modified-Release Drug Delivery Systems: Rate-Programmed II
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

